Cancer Stem Cell News Volume 5.36 | Sep 14 2016

TOP STORY

Inhibition of Interleukin-1 Signaling Enhances Elimination of Tyrosine Kinase Inhibitor Treated CML Stem Cells

The authors showed that chronic myelogenous leukemia stem cells demonstrated increased expression of the IL-1 receptors, IL-1RAP and IL-1R1, and enhanced sensitivity to IL-1-induced NF-κB signaling compared to normal stem cells. [Blood] Abstract

(Ranked by impact factor of the journal)

IL1RAP Antibodies Block IL1-Induced Expansion of Candidate CML Stem Cells and Mediate Cell Killing in Xenograft Models

Researchers showed that primitive chronic myeloid leukemia (CML) cells, in contrast to corresponding normal cells, express a functional IL1 receptor complex and respond with NFKB activation and marked proliferation in response to IL1. IL1RAP antibodies that inhibit IL1 signaling could block these effects. [Blood] Abstract

Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma

Gastric carcinomas (GC) are heterogeneous, and the current therapy remains essentially based on surgery with conventional chemo- and radiotherapy. This study aimed to characterize biomarkers allowing the detection of cancer stem cells in human GC of different histological types. [Clin Cancer Res] Abstract

Lineage-Restricted OLIG2-RTK Signaling Governs the Molecular Subtype of Glioma Stem-like Cells

Investigators showed that OLIG2 modulates growth factor signaling in two distinct populations of glioma stem-like cells, characterized by expression of either the epidermal growth factor receptor or platelet-derived growth factor receptor alpha. [Cell Rep] Full Article | Graphical Abstract

Unravelling the Relevance of CLEC12A as a Cancer Stem Cell Marker in Myelodysplastic Syndrome

Investigators showed that the CD34⁺ CD38^– C-type lectin domain family 12, member A (CLEC12A⁺) cells were indeed malignant and possessed functional stem cell properties in the long-term colony-initiating cell assay. As opposed to reported findings in acute myeloid leukemia, they showed that cancer stem cells from myelodysplastic syndrome samples derived from both CLEC12A positive and negative CD34⁺ CD38^– subpopulations. [Br J Haematol] Full Article

Atg5-Dependent Autophagy Contributes to the Development of Acute Myeloid Leukemia in an MLL-AF9-Driven Mouse Model

Researchers employed a mouse model of acute myeloid leukemia (AML) expressing the fusion oncogene MLL-AF9 and explore the effects of Atg5 deletion, a key autophagy protein, on the malignant transformation and progression of AML. Consistent with a transient decrease in colony-forming potential in vitro, the in vivo deletion of Atg5 in MLL-AF9-transduced bone marrow cells during primary transplantation prolonged the survival of recipient mice, suggesting that autophagy has a role in MLL-AF9-driven leukemia initiation. [Cell Death Dis] Full Article

α-Mangostin-Encapsulated PLGA Nanoparticles Inhibit Pancreatic Carcinogenesis by Targeting Cancer Stem Cells in Human, and Transgenic (Kras^G12D, and Kras^G12D/tp53^R270H) Mice

In order to enhance the biological activity of α-mangostin, researchers formulated mangostin-encapsulated PLGA nanoparticles and examined the molecular mechanisms by which they inhibit human and Pdx^Cre;LSL-Kras^G12D mice pancreatic cancer stem cell characteristics in vitro, and pancreatic carcinogenesis in Pdx^Cre;LSLKras^G12D;LSL-Trp53^R172H mice. [Sci Rep] Full Article

Ultrasonic Surgical Aspirate is a Reliable Source for Culturing Glioblastoma Stem Cells

Scientists showed that ultrasonic aspirate (UA) samples offer a large and reliable source of live cells. Similar to core biopsies, UA samples enriched for glioma stem cells (GSCs) that differentiated into neural lineages, showed inter-individual variation of GSC markers, and induced tumors. [Sci Rep] Full Article

Isolation, Culture and Identification of Choriocarcinoma Stem-Like Cells from the Human Choriocarcinoma Cell-Line JEG-3

The human choriocarcinoma cell line JEG-3 was cultured in serum free media, and the characteristics of suspension and parental adherent JEG-3 cells were compared. [Cell Physiol Biochem] Full Article

Aldehyde Dehydrogenases Inhibition Eradicates Leukemia Stem Cells while Sparing Normal Progenitors

To try to combat the leukemia stem cell population selectively, a well-characterized ALDH inhibitor by the trivial name of dimethyl ampal thiolester was assessed on sorted CD34⁺CD38⁻ subpopulations from AML patients and healthy patients. ALDH activity and cell viability were monitored by flow cytometry. [Blood Cancer J] Full Article

Multidrug-Resistant Cancer Cells and Cancer Stem Cells Hijack Cellular Systems to Circumvent Systemic Therapies, Can Natural Products Reverse This?

A significant effort has been made to identify agents that specifically target multidrug resistance (MDR) cells and cancer stem cells (CSCs). Consequently, some agents derived from nature have been developed with a view that they may overcome MDR and/or target CSCs. In this review, natural products-targeting MDR cancer cells and CSCs are summarized and clustered by their targets in different signaling pathways. [Cell Mol Life Sci] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

SELLAS™ Life Sciences Announces Entry into Cooperative Research and Development Agreement with National Heart, Lung and Blood Institute, National Institutes of Health

SELLAS Life Sciences Group announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US National Heart, Lung and Blood Institute, National Institutes of Health. The research plan of the CRADA is designed to develop a novel AML MRD assay for monitoring the expression of multiple genes that can document the kinetics of minimal residual disease (MRD) in acute myeloid leukemia during treatment with SELLAS’ most advanced product candidate, galinpepimut-S, the company’s WT1 cancer vaccine. [SELLAS Life Sciences Group (PR Newswire Association LLC.)] Press Release

Regen BioPharma, Inc. Responds to FDA on dCellVax Gene-Silenced Breast Cancer Immunotherapy

Regen BioPharma, Inc. announced submission to the Food and Drug Administration (FDA) of a revised Investigational New Drug application focused on using a novel method to unleash the body’s innate ability to kill cancer. The package submitted contained preclinical experiments as well as details of the proposed clinical trial. [Regen BioPharma, Inc. (PR Newswire Association LLC.)] Press Release

Array BioPharma Announces Phase III BEACON CRC SPA Agreement with FDA

Array BioPharma announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment related to BEACON CRC, a global Phase III trial of encorafenib and Erbitux^®, with or without binimetinib, versus standard of care in patients with BRAF-mutant colorectal cancer (CRC) who have previously received first-or second-line systemic therapy. [Array BioPharma] Press Release

A Shady Market in Scientific Papers Mars Iran’s Rise in Science

Iran’s parliament, the Majlis, is expected to take up work on a bill that would outlaw shady practices in scientific publishing. [Science] Editorial

Medical Nobel Prize Committee Deals with Surgical Scandal

In an unprecedented move, the group that selects the winners of the Nobel Prize in Physiology or Medicine — the Nobel Assembly — has asked two of its members to resign following a scandal at the institute that supplies the assembly’s members. [Nature News] Editorial

NEW 2017 Gastrointestinal Cancers Symposium
January 19-21, 2017
San Francisco, United States

NEW Cell Culture and Downstream Processing World Congress
February 21-22, 2017
Munich, Germany

NEW World Advanced Therapies and Regenerative Medicine Congress
May 17-19, 2017
London, United Kingdom

Visit our events page to see a complete list of events in the community.

NEW Cancer Scientists – Clinical and Translational Breast Cancer Research (Hamad bin Khalifa University)

Postdoctoral Fellow – Program Manager (German Cancer Research Center)

Scientific Officer – Peer Review Office (Associazione Italiana per la Ricerca sul cancro)

Postdoctoral Fellow – Laboratory Studies Brain Cancer Stem Cells (Houston Methodist)

Associate Scientist – Epigenetics of Cancer (Celgene Corporation)

Full Professor – Molecular Mechanisms of Tumorigenesis (German Cancer Research Center)

Postdoctoral Position – Metastatic Breast Cancer (Purdue Center for Cancer Research)

Core Staff Scientist (Moffitt Cancer Center)

Principal Investigator – Clinical Geneticist in Pediatric Leukemia (Children´s Cancer Research Institute, St. Anna Kinderkrebsforschung)

Bioinformatician – Bioinformatics Data Analysis (Children´s Cancer Research Institute, St. Anna Kinderkrebsforschung)

Senior Research Assistant – Differentiation and Survival of Leukemia Stem Cells (The University of Texas MD Anderson Cancer Center)

Tenure Track Faculty – Biological Sciences Scholars Program (University of Michigan)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.